Download the full report (112 p.) - KCE

KCE Reports 111 Interventions in Alzheimer’s Disease 51
Table 10. continued.
HTA's reviews Economic evaluations' reviews Models' review
Treatment Reference SBU, NICE- Loveman Oremus, Wimo et al., Wimo et Wimo, Int Kirby et Wimo, Cohen et Green,
2008 SCIE, et al., 2008 Alzh Dem, al., Expert Psycho, al., 2006 2004 al., 2008 2007
2006 2006
2007 Rev, 2007 2007
Time coverage of the literature review : 07/2004 2006 02/2004 12/2007 07/2004 07/2004 07/2004 07/2004 07/2003 2005 12/2005
Galantamine Caro J, Salas M, Ward A, Getsios D, et al. Assessing the health and economic impact of galantamine treatment in
patients with AD in the health care systems of different countries. Drugs & Aging 2004; 21(10):677-86
x x x
Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G, et al. Economic evaluation of
galantamine in the treatment of mild to moderate AD in the United States. Clin Ther 2003;25:1806-25.
x x ( x ) x x x x x x
Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R, et al. Assessment of health economics in Alzheimer's
disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003;18:740-7.
x x x x x x x x x
Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Assessment of Health Economics in Alzheimer's Disease
(AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20:629-37.
x x ( x ) x x x x x x
Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine in the treatment of patients with
mild to moderate Alzheimer's disease in The Netherlands. Dement Geriatr Cogn Disord 2002;14:84-9.
x x x x x x x x
Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD):
galantamine treatment in Canada. Neurology 2001;57:972-8.
x x ( x ) x x x x x x
Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. Assessment of health economics in Alzheimer's disease
(AHEAD) based on need for full-time care. Neurology 2001;57:964 -71.
x x
Memantine Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate
to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-26.
x
Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, et al. Cost-effectiveness of memantine in
moderate-to-severe AD patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187-97.
x
Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in communitybased
AD patients: An adaptation in Spain.[see comment]. Eur J Health Econ. 2006;7(2):137-44.
x
Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr
Pharmacother. 2005;3(2):77-86.
x x x x x
François C, Sintonen H, Sulkava R. The costeffectiveness of memantine in moderately severe to severe Alzheimer’s
disease. A Markov model in Finland. Clin Drug Invest 2004;27:373–84.
x x x x x x x x
Jones R, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a
probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21:607–20.
x x x x x x x x x
Wimo A. Winblad B. Stoffler A. Wirth Y. Mobius HJ. Resource utilisation and cost analysis of memantine in patients
with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21(5):327-40
(( x )) (( x ))
Non-drug Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, et al. Cognitive stimulation therapy for people with
dementia: cost-effectiveness analysis. British Journal of Psychiatry. 2006;188:574-80.
x
Martikainen J, Valtonen H, Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer's
disease patients. Eur J Health Econ. 2004;5(2):136-42.
x x x x x
Nocera S, Bonato D, Telser H. The contingency of contingent valuation. How much are people willing to pay against
Alzheimer’s disease? Int J Health Care Finance Econ 2002;2:219-40.
x x x
Roberts, J., Browne, G., Milne, C., et al. Problem-solving counseling for caregivers of the cognitively impaired:
effective for whom? Nursing Research 1999; 48: 162-172.
x
McGuire, R.C. (1998) A case study in CEA for computer technology used in support of caregivers with AD patients. In
Information Systems Innovations for Nursing (eds. Moorhead&Delaney). CA: Sage Publications.
x
Wimo A, Mattson B, Krakau I, Eriksson T, Nelvig A, Karlsson G. Costutility analysis of group living in dementia care.
Int J Technol Assess Health Care 1995;11:49-65.
x x x
Wimo A, Mattsson B, Krakau I, Eriksson T, Nelvig A. Cost-effectiveness analysis of day care for patients with
dementia disorders. Health Econ 1994;3:395-404.
x x x
Brodaty, H. & Peters, K.E. Cost
Psychogeriatrics 1991; 3, 11-22.
effectiveness of a training program for dementia carers. International
( x ) x
Drummond MF, Mohide EA, Tew M, Streiner DL, Pringle DM, Gilbert JR. Economic evaluation of a support program
for caregivers of demented elderly. Int J Technol Assess Health Care 1991;7:209-19.
x x x x
Wimo A, Wallin JO, Lundgren K, Ronnback E, Asplund K, Mattsson B, et al. Impact of day care on dementia
patients – costs, well-being and relatives’ views. Fam Pract 1990;7:279-87.
x x